What the Daniel Murphy Paradigm Peptides case actually is

Record status, last checked

Last verified: 2026-08-01 UTC. This is a status record, not legal advice.

The Daniel Murphy Paradigm Peptides case is not an AI-sanctions matter. The confirmed criminal record is United States v. Kawa, No. 3:25-cr-00091, in the U.S. District Court for the Northern District of Indiana, where Matthew Kawa, owner of Paradigm Peptides / Paradigm R.E. LLC, and Jennifer L. Stechkober were sentenced on July 30, 2026, before Judge Cristal C. Brisco.[1] The separate civil record is a Los Angeles County Superior Court product-liability filing by Daniel J. Murphy and Laura Murphy against Paradigm Peptides, Matthew Kawa, and Jennifer L. Stechkober, filed February 25, 2026; at this check, that civil complaint is being treated as docket-metadata verified only, because the complaint itself has not been reviewed here.[2][3]

That classification matters. A reader checking the phrase “Daniel Murphy Paradigm Peptides case” may be trying to determine whether this belongs with AI-citation sanction records. It does not. It is closer to an exceptional non-AI legal-risk status record: a real enforcement record, a real sentencing event, and a related civil filing that still needs complaint-level confirmation. For contrast, actual AI-citation entries turn on the use of false or AI-generated authorities, as in an AI-sanction record.

The criminal record: plea to sentencing

The criminal case is the stable record. Kawa and Stechkober pleaded guilty on December 10, 2025, to selling unapproved new drugs and illegally importing them; the DOJ case page describes products labeled as SARMs that tested positive for testosterone, a controlled substance.[1]

On July 30, 2026, Kawa was sentenced to 70 months in prison and one year of supervised release. Stechkober was sentenced to 16 months in prison and one year of supervised release. The court also imposed restitution of $78,317.52 jointly and severally, special assessments of $200 for Kawa and $100 for Stechkober, and a $5 million money judgment against Kawa.[1]

Customer scale and restitution requests are different measurements

The DOJ case page uses the broader formulation “thousands of customers.”[1] CBS News reported prosecutors’ estimate of roughly 54,000 unique customers across all 50 states and 80 countries.[5] Sentencing-material reporting tied to Doc. 64 identifies 167 victim restitution requests, but the currently available PacerMonitor material should be re-verified before anyone quotes the filing text directly.[6]

Those figures are not interchangeable. A customer estimate measures reach. A restitution-request count measures the set of people who submitted claims through a sentencing process. The $78,317.52 restitution figure is the court-recorded amount; it is not a finding that only 167 people bought products, and it is not a civil damages adjudication for Murphy or anyone else.[1][6]

Where Daniel J. Murphy fits

Daniel J. Murphy appears in the related civil track, not as a criminal defendant and not as an AI-sanctions figure. UniCourt identifies a Los Angeles County Superior Court case filed February 25, 2026, with Daniel J. Murphy and Laura Murphy as plaintiffs and Paradigm Peptides, Matthew Kawa, and Jennifer L. Stechkober as defendants; the case type is listed as Personal Injury/Torts – Product Liability.[2] Trellis separately lists a complaint filed by Daniel J. Murphy and Laura Murphy against the same named defendants.[3]

The complaint-level allegations are not restated here as verified pleadings, because the Los Angeles Superior Court complaint itself was not reviewed for this record. The only civil facts treated as currently usable are the filing date, parties, court, and case-type metadata from UniCourt and Trellis.[2][3]

Reported narrative fills in why Murphy’s name is attached to this matter, but it does not decide liability. BBC reported that Murphy was 32, worked as a marketing consultant, bought a fitness supplement online, was diagnosed by consultant psychiatrist Dr. Erik Messamore with steroid-induced psychosis, and had a retained bottle independently tested positive for testosterone.[7] CBS reported that Kawa is contesting the civil suit.[5]

What the pending California suit can and cannot prove today

The California filing should be tracked because it may become the place where product-liability allegations, causation theories, damages claims, and defenses are tested. It should not be made to do that work prematurely. Docket metadata can establish that a product-liability case was filed, who is named, and where it is pending; it does not substitute for the complaint, answer, demurrer, discovery record, expert record, or judgment.[2][3]

The criminal restitution order also should not be imported wholesale into the civil case. Restitution in the federal criminal case was imposed as part of the sentencing record against Kawa and Stechkober.[1] Murphy’s reported injury account and the Murphys’ civil pleading track require their own source chain before being summarized beyond the docket-level fields and attributed reporting already identified.

Why this is not an AI hallucination case

Charlotin’s AI Hallucination Cases Database, which listed 1,811 cases, including 1,252 U.S. cases, and was updated on July 29, 2026, contains no Paradigm Peptides or Murphy entry at this check.[4] Targeted searches for an AI-tool, hallucinated-citation, or attorney-sanction angle likewise did not produce a confirmed AI component. That is a negative classification finding, not a claim that no person anywhere has ever mentioned the matter in an AI-related discussion.

The boundary is narrow but important: this is a legal-risk record involving drug enforcement, sentencing, restitution, and pending product-liability litigation. It is not evidence of an attorney filing invented authorities, a court sanctioning counsel for AI misuse, or a judge analyzing generative-AI reliability.

Peptide-vendor context, kept narrow

The broader peptide market explains why this record may draw attention, but it does not change the verified case fields. Public Citizen has described the peptide craze and identified United States v. Kawa as part of that enforcement environment.[8] The Markup’s earlier reporting on “research use only” sales practices provides context for how some vendors marketed products while avoiding conventional consumer-drug framing.[9]

That background is useful only to a point. The confirmed record here remains the federal criminal case, the sentencing terms, the restitution and money judgment, and the separate pending California product-liability docket. Market commentary cannot verify Murphy’s complaint allegations, and it cannot supply an AI angle that the record does not contain.

Operational status

As of the current check, United States v. Kawa is a confirmed Northern District of Indiana criminal case with July 30, 2026 sentencing outcomes, $78,317.52 restitution, special assessments, supervised release terms, and a $5 million money judgment against Kawa.[1] The Daniel J. Murphy and Laura Murphy California product-liability suit is pending verification beyond UniCourt and Trellis docket metadata.[2][3] No AI-hallucination, AI-citation, or attorney-sanction element is present in the verified record.[4]

References

1. Northern District of Indiana | United States v. Matthew Kawa — U.S. Attorney’s Office, Northern District of Indiana
2. UniCourt docket for the civil case — UniCourt
3. Complaint Filed by Daniel J Murphy Plaintiff Laura Murphy Plaintiff as to Paradigm Peptides a Delaware Corporation Qualified to Do Business in State California Defendant Matthew Kawa Defendant Jennifer L Stechkober Defendant — Trellis
4. AI Hallucination Cases Database — Damien Charlotin, updated 2026-07-29
5. Judge sentences peptide vendor to nearly 6 years in prison... — CBS News
6. PacerMonitor Doc 64 government sentencing memorandum — PacerMonitor
7. He bought a fitness supplement online to bulk up, but ended up losing his mind — BBC
8. The “Miracle Drug” and the Peptide Craze Breaking the FDA — Public Citizen
9. Amazon’s Sales of Peptides and Doping Drugs — The Markup, 2020